Brookline Capital Markets Cuts Forte Biosciences FY2026 Earnings Forecast

Analysts Expect Larger Near-Term Losses for Biotech Firm

Apr. 9, 2026 at 11:05am

Got story updates? Submit your updates here. ›

An extreme close-up of gears, levers, and other heavy industrial machinery in muted metallic tones, representing the complex financial mechanisms underlying a biotech company's fortunes.The complex inner workings of the financial industry are laid bare, hinting at the institutional forces shaping Forte Biosciences' path forward.San Diego Today

Analysts at Brookline Capital Markets have sharply reduced their multi-year earnings projections for Forte Biosciences, Inc. (NASDAQ:FBRX), cutting earlier estimates across several years. The revisions signal the analyst expects larger near-term losses than previously modeled, which amplifies negative sentiment from the company's recent $150 million public stock offering.

Why it matters

The reduced earnings forecasts from Brookline Capital Markets suggest the analyst has a more pessimistic outlook on Forte Biosciences' near-term financial performance, which could impact investor confidence in the biotech firm as it works to advance its lead product candidate FB-401 for atopic dermatitis.

The details

In a research note issued on Monday, April 6th, Brookline Capital Markets analyst K. Raja decreased the firm's FY2026 earnings estimates for Forte Biosciences. The analyst now anticipates the company will post earnings per share of ($4.44) for the year, down from their prior forecast of ($2.72). Brookline Capital Markets also issued reduced estimates for Forte Biosciences' FY2027 ($3.26 EPS), FY2028 ($2.92 EPS), and FY2029 ($7.49 EPS).

  • Brookline Capital Markets issued the updated earnings estimates on Monday, April 6th, 2026.

The players

Brookline Capital Markets

An investment banking and securities firm that provides research coverage on Forte Biosciences.

K. Raja

An analyst at Brookline Capital Markets who covers Forte Biosciences.

Forte Biosciences, Inc.

A clinical-stage biotechnology company focused on developing treatments to restore skin health by targeting the skin barrier and microbiome.

Got photos? Submit your photos here. ›

What they’re saying

“Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings per share of ($4.44) for the year, down from their prior forecast of ($2.72).”

— K. Raja, Analyst

What’s next

Investors will be closely watching Forte Biosciences' upcoming financial results and pipeline updates to gauge the accuracy of Brookline Capital Markets' reduced earnings forecasts.

The takeaway

The sharp cuts to Brookline Capital Markets' multi-year earnings projections for Forte Biosciences suggest the analyst has growing concerns about the biotech firm's near-term financial performance, which could weigh on investor sentiment as the company works to advance its lead atopic dermatitis treatment.